<DOC>
	<DOCNO>NCT00031837</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , work different way stop tumor cell divide stop grow die . Anticoagulants dalteparin may help prevent blood clot patient treat gemcitabine unresectable metastatic pancreatic cancer . PURPOSE : Randomized phase III trial compare effectiveness gemcitabine without dalteparin treat patient unresectable metastatic pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine With Without Dalteparin Treating Patients With Unresectable Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare quality life patient unresectable metastatic pancreatic cancer treat gemcitabine without dalteparin . - Compare survival patient treat regimen . - Compare incidence venous thromboembolic complication patient treat regimen . - Determine safety dalteparin , term bleed complication , patient . OUTLINE : This randomize , multicenter study . Patients stratify accord disease stage ( unresectable nonmetastatic v metastatic ) . Patients randomize one two treatment arm . - Arm I : Patients receive gemcitabine IV 30 minute weekly week 1-7 first course . Beginning week 9 , patient receive gemcitabine IV 30 minute weekly 3 week . Treatment repeat every 4 week 6 month absence unacceptable toxicity disease progression . - Arm II : Patients receive gemcitabine arm I dalteparin subcutaneously daily 6 month absence unacceptable toxicity . Quality life assess baseline every 4 week study therapy . Patients follow every 4 week . PROJECTED ACCRUAL : A total 400 patient ( 200 per treatment arm ) accrue study within 40 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm pancreatic adenocarcinoma poorly differentiate carcinoma pancreas consider ineligible curative resection PATIENT CHARACTERISTICS : Age : 18 Performance status : Eastern Cooperative Oncology Group 02 Life expectancy : Not specify Hematopoietic : White Blood Cell count great 3,500/mm^3 Platelet count great 100,000/mm^3 No clinically significant bleed disorder No prior heparininduced thrombocytopenia Hepatic : Bilirubin le 2.0 mg/dL aspartate aminotransferase less 3 time normal Renal : Creatinine le 2.0 mg/dL Cardiovascular : No prior hemorrhagic stroke No uncontrolled hypertension ( sustain blood pressure great 200 mm Hg systolic 110 mm Hg diastolic ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active malignancy No gastrointestinal bleeding within past 30 day No contraindication anticoagulation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy metastatic disease Prior adjuvant chemotherapy allow Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : Prior surgical resection allow At least 4 week since prior surgery noncurative intent recover More 30 day since prior neurologic ophthalmologic surgery Other : At least 2 week since prior lowmolecularweight heparin More 30 day since prior experimental therapeutic agent No concurrent heparin warfarin preexist condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>thromboembolism</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>